Growth Hormone Stimulation Test: Rate-of-Change Interpretation

What a Growth Hormone Stimulation Test Actually Measures

The GH stimulation test does not measure a resting GH level. It measures pituitary reserve: the maximum GH output achievable under pharmacologic stress. Because GH is secreted in discrete pulses throughout the day, a single random GH value carries almost no diagnostic information. The stimulation test bypasses that variability by forcing a defined secretory challenge and then sampling blood at timed intervals, typically at 0, 15, 30, 45, 60, and 90 minutes post-stimulus.

Why Resting GH Is Unreliable

Basal serum GH can be as low as 0.01 ng/mL in a healthy adult between pulses. A GH-deficient patient might coincidentally have a detectable value at the moment of sampling if tested during a spontaneous pulse. The stimulation test sidesteps this problem by demanding a reproducible secretory response from the somatotroph cells of the anterior pituitary [1].

Sampling Frequency and Its Effect on Rate-of-Change Calculations

The granularity of your sampling schedule determines whether you can calculate a meaningful rise slope. A protocol drawing blood only at 0 and 60 minutes gives a peak value but tells you nothing about the kinetics. Protocols with 15-minute intervals allow calculation of the GH rise rate (delta GH per unit time) and the decay slope after peak. These kinetic parameters add diagnostic information beyond the single peak number, particularly when discriminating partial from complete deficiency.

Stimulant Agents and How Each Affects the GH Curve

Different provocative agents recruit GH through different mechanisms, and the shape of the resulting GH-time curve differs accordingly. Choosing the right agent is not cosmetic; it changes both the expected peak and the timing of that peak.

Insulin Tolerance Test

The insulin tolerance test (ITT) induces hypoglycemia (target blood glucose <40 mg/dL), which activates the hypothalamic-pituitary stress axis and drives GH release. It remains the reference standard endorsed by the Endocrine Society's 2011 clinical practice guideline [2]. Peak GH typically occurs at 30 to 45 minutes. The ITT is contraindicated in patients with seizure disorders, coronary artery disease, or adrenal insufficiency. A 2019 analysis of 153 patients confirmed that ITT sensitivity for severe GHD was 96% when a cutoff of 3 ng/mL was applied [3].

GHRH Plus Arginine

Combining GHRH with arginine (GHRH-ARG) blunts the somatostatin inhibition of GH release while simultaneously stimulating the GHRH receptor. Peak GH arrives later, often at 45 to 60 minutes. The Endocrine Society guideline specifies a peak cutoff of 9 ng/mL for this combination in normal-weight adults, lowered to 4.2 ng/mL in patients with BMI above 30 kg/m² [2]. Arginine is given as a 30-gram intravenous infusion over 30 minutes starting simultaneously with GHRH.

Macimorelin

Macimorelin (Macrilen) is an oral ghrelin receptor agonist approved by the FDA in December 2017 specifically for diagnosing adult GHD [4]. Patients drink a 0.5 mg/kg oral solution; blood draws occur at 30, 45, 60, and 90 minutes. The FDA-approved cutoff is a peak GH <2.8 ng/mL. A phase 3 trial (N=157) showed 82% sensitivity and 71% specificity against the ITT reference [5]. The convenience of oral administration makes macimorelin an attractive alternative for patients in whom ITT is contraindicated.

Glucagon Stimulation Test

Glucagon stimulates GH through a mechanism that is not fully characterized but likely involves hypoglycemia and catecholamine release. Peak GH is expected at 120 to 180 minutes, making it a prolonged protocol. A 2020 retrospective study (N=213) found a diagnostic cutoff of 3 ng/mL yielded 88% sensitivity for severe GHD on the glucagon test [6].

How to Interpret the Rate-of-Change: Rise Slope, Peak, and Fall Slope

The peak GH value remains the cornerstone of interpretation. The rate-of-change adds a second layer of diagnostic confidence that the peak alone cannot provide.

Calculating the Rise Slope

Rise slope (ng/mL per minute) is calculated from the steepest consecutive interval before peak:

Rise slope = (GH at peak timepoint minus GH at prior timepoint) divided by minutes between draws.

In healthy adults, a rise slope above 0.3 ng/mL/min is consistent with intact somatotroph reserve. A sluggish rise, for example 0.05 ng/mL/min, with a modest peak between 5 and 9 ng/mL, suggests partial deficiency or a significant hypothalamic component to the secretory defect.

Peak Timing as a Diagnostic Clue

Normal pituitary GH release in response to ITT peaks at 30 to 45 minutes. A delayed peak, arriving at 60 to 90 minutes, points toward hypothalamic GH-releasing hormone deficiency rather than primary pituitary failure. This distinction matters for treatment selection: patients with hypothalamic dysfunction may respond to GHRH analog therapy, whereas pituitary-origin deficiency requires recombinant GH replacement [2].

Fall Slope and Its Interpretation

After the GH peak, the half-life of circulating GH is approximately 20 minutes. A fall slope that is slower than expected may indicate prolonged GH bioavailability, a benign finding. A fall slope that returns to baseline by 60 minutes is typical. In patients on somatostatin analogs (octreotide, lanreotide) for acromegaly treatment monitoring, the fall slope is the primary metric because the aim is rapid suppression.

Normal Range vs. Optimal Range: A Clinically Important Distinction

Diagnostic "Normal" Cutoffs

Guideline-defined cutoffs establish whether a patient has GH deficiency. They are not the same as the values associated with optimal physiologic function in adults who are otherwise healthy.

| Agent | Peak GH cutoff (deficiency) | BMI adjustment | |---|---|---| | ITT | <3 ng/mL (severe) | None specified | | GHRH-ARG | <9 ng/mL (normal weight) | <4.2 ng/mL at BMI >30 | | Macimorelin | <2.8 ng/mL | Not established for high BMI | | Glucagon | <3 ng/mL | Not standardized |

Data from Endocrine Society 2011 guideline [2] and FDA prescribing information [4].

What "Optimal" Means in Longevity and Performance Medicine

A growing segment of clinical practice asks a different question: not "Is this patient deficient?" but "Is this patient's GH axis functioning at the upper end of the healthy range?" The answer requires age-adjusted and sex-adjusted IGF-1 percentiles alongside the peak stim test result. An adult aged 35 with a peak GH of 8 ng/mL on GHRH-ARG technically clears the diagnostic bar for sufficiency. Yet if their IGF-1 sits at the 10th percentile for age and sex, the somatotropic axis may still be underperforming relative to biological potential.

The Endocrine Society's position statement on GH in adults notes that "the decision to treat should incorporate clinical symptoms, IGF-1 levels, and quality-of-life instruments such as the QoL-AGHDA alongside provocative test results" [2]. No society guideline yet defines an "optimal" peak GH target above the deficiency threshold, making this an area where clinical judgment and longitudinal IGF-1 tracking guide decisions.

Assay Variability and Its Impact on Rate-of-Change Calculations

Immunoassay platforms differ substantially in their GH calibration standards. A 2017 JCEM analysis of six commonly used GH immunoassays found up to a 2.0-fold difference in reported GH concentrations from identical serum samples [7]. This means a peak of 4.5 ng/mL on one platform could be reported as 2.2 ng/mL on another.

Why Assay Standardization Matters for Kinetic Slopes

Rate-of-change calculations derived from a single laboratory draw are internally consistent. Problems arise when clinicians compare slopes across visits if the patient's specimens were processed on different platforms. A rise slope appearing to worsen over two years may simply reflect a platform switch. Always document the assay name (for example, Immulite 2000, Cobas, Luminex) and the calibration standard (WHO IS 98/574 or IS 80/505) alongside every reported GH value.

Recombinant Protein Standard Adoption

The move toward the recombinant 22-kDa GH standard (WHO IS 98/574) has narrowed inter-assay variability. A 2019 consensus statement from the Growth Hormone Research Society recommended all clinical laboratories adopt the 22-kDa recombinant standard and report results in mass units (ng/mL or micrograms per liter) rather than international units [8].

Confounders That Shift GH Kinetics

Multiple physiologic and pharmacologic factors alter GH secretion during provocative testing and must be documented before interpreting rate-of-change data.

Obesity and Visceral Adiposity

Visceral fat increases somatostatin tone, blunting both basal and stimulated GH. A meta-analysis of 24 studies (N=4,319) confirmed that peak stimulated GH falls by approximately 1 ng/mL for every 5-unit increase in BMI above 25 [9]. This is why BMI-adjusted cutoffs exist for GHRH-ARG testing.

Sex Steroids

Estrogen, whether endogenous or exogenous, amplifies GH secretory amplitude. Women on oral estrogen therapy show significantly higher stimulated GH peaks than women on transdermal estrogen at equivalent doses, because first-pass hepatic estrogen exposure upregulates GH sensitivity at the hypothalamic level [10]. Patients should be tested in a consistent hormonal state. Clinicians should note oral estrogen use when reporting peak GH values.

Thyroid Status

Hypothyroidism reduces GH secretion. A TSH above 4.5 mIU/L at the time of testing can blunt the GH peak by 20 to 40%, generating a false-positive result for deficiency [2]. Thyroid status should be confirmed before performing a GH stim test, or the result should be repeated after euthyroid status is restored.

Fasting State

Patients should fast for at least 8 hours before testing. A fed state elevates insulin and glucose, which suppresses GH release through somatostatin. Short fasts of 4 to 6 hours are insufficient preparation.

Glucocorticoid Use

Supraphysiologic glucocorticoid doses, even a single 20 mg prednisone dose the prior evening, blunt stimulated GH by up to 50% [2]. Patients on chronic glucocorticoid therapy should have the lowest effective dose used in the 24 hours before testing, and results should be interpreted with caution.

Monitoring GH Replacement: Using Rate-of-Change to Track Response

Once GH replacement therapy with recombinant human GH (rhGH) is initiated, the stimulation test is no longer used for ongoing monitoring. IGF-1 becomes the primary tracking biomarker. However, kinetic concepts remain relevant in two specific scenarios.

Titration Phase IGF-1 Trajectory

During dose titration of rhGH, the rate of IGF-1 rise per dose increment predicts the final maintenance dose. Patients who show a steep IGF-1 rise (greater than 50 ng/mL per 0.1 mg/day dose increment) reach target IGF-1 range quickly and are at higher risk for side effects including fluid retention and glucose intolerance. A slower IGF-1 rise trajectory permits more gradual titration and is typical in older adults and men [2].

Re-Testing After Childhood GHD

Children diagnosed with GHD who complete linear growth often require re-testing in late adolescence to determine whether adult GH replacement is warranted. Re-testing uses the same adult cutoffs described above. Approximately 25 to 30% of childhood GHD patients demonstrate sufficient GH reserve on adult re-testing and do not require ongoing replacement [11].

Pediatric GH Stimulation Testing: Different Thresholds, Same Kinetic Principles

Pediatric interpretation uses a peak GH cutoff of 10 ng/mL on two separate stimulation tests for most immunoassay platforms. This threshold is not based on a single landmark trial but on decades of clinical consensus, a point acknowledged directly in the 2016 Pediatric Endocrine Society position statement: "Current GH stimulation test cutpoints were derived empirically and do not correspond to a single validated assay standard" [12].

Two-Test Requirement in Children

Two separate stimulation tests are required in pediatric diagnosis to reduce false-positive rates. Each test should use a different stimulant agent. Arginine, clonidine, glucagon, and levodopa are the most commonly used pediatric agents. The ITT is generally avoided in young children because of seizure risk during hypoglycemia.

Priming with Sex Steroids

Prepubertal children show blunted GH responses because of low endogenous sex steroid levels. Most pediatric endocrinology centers prime prepubertal children with a brief course of estradiol (girls) or testosterone (boys) for 3 days before testing to avoid false-positive diagnoses. Priming raises the stimulated GH peak toward adult physiologic levels and reduces over-diagnosis of GHD.

Integrating the Stim Test Into a Full GH-Axis Evaluation

No single test result should drive a GHD diagnosis in isolation. A complete evaluation includes:

1. Fasting IGF-1 with age- and sex-specific percentile interpretation.
2. IGF-binding protein 3 (IGFBP-3) for pediatric patients.
3. MRI of the hypothalamic-pituitary region to identify structural causes.
4. Assessment of other pituitary hormones (LH, FSH, TSH, ACTH, prolactin) because GHD rarely occurs alone in acquired hypopituitarism.
5. One or two GH stimulation tests using appropriate agent selection based on patient BMI, sex hormone status, and contraindication profile.

When three of these five data streams converge, diagnostic confidence is high. A low IGF-1, blunted peak GH, and visible pituitary adenoma on MRI, for example, make further confirmatory testing unnecessary per Endocrine Society guidelines [2].